RECRUITINGINTERVENTIONAL
No-Reflow in Patients With STEMI After Intracoronary Tirofiban After Opening of the Track
Assessment of No-Reflow in Patients With STEMI After Intracoronary Tirofiban After Opening of the Track
About This Trial
This study aims to assess the no-reflow in patients with STEMI after intracoronary glycoprotein IIb/IIIa inhibitors after opening of track in thrombus.
Who May Be Eligible (Plain English)
Who May Qualify:
- Age ≥ 18 years old.
- Both sexes.
- Patients with STEMI. ST-segment elevated myocardial infarction is defined as typical chest pain \>30 minutes with ST-segment elevation of \>1 mm in at least 2 consecutive leads on the electrocardiogram or new-onset left bundle brunch block.
Who Should NOT Join This Trial:
- Treatment with thrombolytic drugs in the previous 24 hours.
- Known malignancy.
- Thrombocytopenia.
- End-stage liver disease.
- Cardiogenic shock.
- Renal failure with glomerular filtration\<30 ml/min.
- Contraindication for the use of tirofiban.
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Age ≥ 18 years old.
* Both sexes.
* Patients with STEMI. ST-segment elevated myocardial infarction is defined as typical chest pain \>30 minutes with ST-segment elevation of \>1 mm in at least 2 consecutive leads on the electrocardiogram or new-onset left bundle brunch block.
Exclusion Criteria:
* Treatment with thrombolytic drugs in the previous 24 hours.
* Known malignancy.
* Thrombocytopenia.
* End-stage liver disease.
* Cardiogenic shock.
* Renal failure with glomerular filtration\<30 ml/min.
* Contraindication for the use of tirofiban.
Treatments Being Tested
DRUG
Intracoronary tirofiban
Patients will receive intracoronary tirofiban (Aggrastat®) (25 mg/kg).
DRUG
Saline 0.9%
Patients will receive intracoronary saline 0.9% solution as a control group.
Locations (1)
Kafrelsheikh University
Kafr ash Shaykh, Kafrelsheikh, Egypt